Enhanced Chemical Structure Visualization-A New Turn for Cheminformatics

By CIOReview | Friday, March 7, 2014

CAMBRIDGE,MS: Cambridge Semantics, provider of Unified Information Access solutions for enterprises recently announced that it has partnered with ChemAxon to provide customers with advanced chemical search and visualization capabilities.

Cambridge Semantics is known for their Anzo software suite, which helps enterprises to leverage, understand and combine data from diverse sources and tackle all kinds of business problems. While ChemAxon caters cheminformatics software platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical industries. This software company possesses core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design.

With the integration, Anzo customers have developed the ability to visualize chemical structures within their Anzo Web dashboards and can now perform chemical structure searches over their existing databases that contain chemical data by directly drawing substructures.

 “With ChemAxon integrated into Anzo software, pharma companies can more easily find all of the papers related to a particular chemical substructure in patent information, publications and other drug research databases,” says Lee Feigenbaum, co-founder and vice president of marketing and technology for Cambridge Semantics.

On the other hand, ChemAxon customers after the amalgamation can easily integrate other sources of data with their chemical structure data and is also being able to quickly setup searchable knowledge bases and dashboards of chemical data combined with any other related data by the help of Anzo’s easy-to-use tools.

“The combined power of our robust chemistry search and visualization capabilities with Anzo’s ability to find highly useful information quickly will be a huge benefit to global pharma companies as well as major chemical and agrochemistry companies, biotech enterprises and academic research centers,” says Alex Drijver, CEO of ChemAxon.